MRC1 and colorectal cancer: The result of CRC has shown that the immune-related objective response rate and immune-related progression-free survival rate were 40% and 78%, respectively, for dMMR colorectal cancers and 0% and 11% for MMR–proficient (pMMR) colorectal cancers [42].